AtaiBeckley N.V. Overview
AtaiBeckley N.V. is a clinical-stage biopharmaceutical company formed in November 2025 through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited. The company focuses on developing effective, rapid-acting, and convenient treatments for mental health conditions, aiming to transform patient outcomes. Its pipeline includes novel therapies such as BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression, VLS-01 (buccal film DMT) for treatment-resistant depression, and EMP-01 (oral R-MDMA) for social anxiety disorder, all in Phase 2 clinical development. Additionally, AtaiBeckley is advancing a drug discovery program to identify non-hallucinogenic 5-HT2AR agonists for opioid use disorder and treatment-resistant depression.
Is AtaiBeckley N.V. the right investor for your startup? Browse their investment focus, stage preferences, and geographic scope to see how well they align with your fundraising goals. Your full match score with AtaiBeckley N.V., along with a list of other relevant VCs, is available on Hopohopo.io.
AtaiBeckley N.V.
Investment focus
Product type
- Drugs / Pharma
Industries / verticals
- Digital & Consumer health
Stages
Series B or later
First ticket size
US$150,000,000 - US$150,000,000
How to approach funds like AtaiBeckley N.V.
When approaching AtaiBeckley, founders should highlight differentiated clinical data, robust translational science, and a clear regulatory strategy for neuropsychiatric indications. Demonstrating a strong understanding of the mental health treatment landscape and how your solution addresses unmet needs or improves patient access will resonate. Emphasize partnerships with leading academic or clinical institutions and a credible plan for advancing through clinical milestones, as AtaiBeckley values rigorous, evidence-driven development and scalable impact.
Find the best-fitting investors for your startup
Stop wasting weeks searching for the right investors. Upload your deck and get matched with investors who actually fit your startup — so you can focus on building, not chasing.
